Conversion to colistin susceptibility by tigecycline exposure in colistin-resistant Klebsiella pneumoniae and its implications to combination therapy

Objectives: This study investigated the effect of tigecycline exposure on susceptibility of colistin-resistant Klebsiella pneumoniae isolates to colistin and explored the possibility of antibiotic combination at low concentrations to treat colistinresistant K. pneumoniae isolates. Methods: Twelve tigecycline-resistant (TIR) mutants were induced in vitro from wild-type, colistinresistant, and tigecycline-susceptible K. pneumoniae isolates. Antibiotic susceptibility was determined us-ing the broth microdilution method. The deduced amino acid alterations were identified for genes asso-ciated with colistin resistance, lipid A biosynthesis, and tigecycline resistance. Expression levels of genes were compared between wild-type stains and TIR mutants using quantitative real-time polymerase chain reaction (PCR). Lipid A modification was explored using MALDI-TOF mass spectrometry. Time-killing as-say was performed to assess the efficiency of combination therapy using low concentrations of colistin and tigecycline.Results: All TIR mutants except one were converted to be susceptible to colistin. These TIR mutants had mutations in the ramR gene and increased expression levels of ramA. Three genes associated with lipid A biosynthesis, lpxC, lpxL, and lpxO, were also overexpressed in TIR mutants, although no mutation was observed. Additional polysaccharides found in colistin-resistant, wild-type strains were modified in TIR mutants. Colistin-resistant K. pneumoniae strains were eliminated in vitro by combining tigecycline and colistin at 2 mg/L. In this study, we found that tigecycline exposure resulted in reduced resistance of colistin-resistant K. pneumoniae to colistin. Such an effect was mediated by regulation of lipid A modification involving ramA and lpx genes. Conclusion: Because of such reduced resistance, a combination of colistin and tigecycline in low concentrations could effectively eradicate colistinresistant K. pneumoniae strains.(c) 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.